Juno Biomedical, Inc was founded on a vision that it is possible for modern medicine to treat the root cause of disease. We are driven to do more than treat the symptoms; our mission is to give life back to those who have suffered a loss of function due to neurological damage after a stroke by developing a device that enhances the body’s natural reparative process to reverse the damage. CELLTech™ has been developed under an issued patent. The Juno Biomedical, Inc. team has been working closely with the FDA since 2018 as part of the Early Feasibility Study (EFS) Program. The purpose of the EFS program is to fast-track highly novel devices to the clinic. We are also in the process of working closely with federal funding bodies to support the CELLTech™ feasibility clinical trial.
